TREM2 in Amyotrophic Lateral Sclerosis
Overview
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a cell surface receptor primarily expressed on microglia in the central nervous system. While extensively validated in Alzheimer's Disease, TREM2's role in Amyotrophic Lateral Sclerosis (ALS) represents a promising yet under-explored therapeutic target. This mechanism page explores the biological rationale for targeting TREM2 in ALS and identifies research gaps.
TREM2 Biology and Microglial Function
TREM2 is a transmembrane receptor belonging to the immunoglobulin superfamily, expressed predominantly on microglia and peripheral macrophages. Its ligand binding triggers signaling through the adaptor protein TYROBP (DAP12), leading to activation of downstream pathways including [SYK](/proteins/syk-protein), [PI3K](/mechanisms/pi3k-akt-signaling), and [MAPK](/mechanisms/mapk-signaling) cascades.
Key microglial functions mediated by TREM2:
- Phagocytosis: TREM2 signaling enhances clearance of debris, apoptotic cells, and protein aggregates
- Cytokine regulation: Modulates production of inflammatory cytokines including [IL-6](/proteins/il6-protein), [TNF-α](/proteins/tnf-alpha), and [IL-1β](/proteins/il1-beta)
- Metabolic adaptation: Supports microglial lipid metabolism and mitochondrial function
- Cell survival: Provides pro-survival signaling through [AKT](/proteins/akt1-protein) activation
ALS Pathophysiology and Microglial Involvement
TDP-43 Proteinopathy
ALS is characterized by cytoplasmic inclusions of TDP-43 protein in motor neurons and glial cells. TDP-43 pathology is present in >95% of ALS cases and is a hallmark of the disease. Unlike Alzheimer's Disease which features amyloid-beta and tau aggregates, ALS involves TDP-43 mislocalization and aggregation.
Microglial Activation in ALS
Post-mortem studies and animal models demonstrate robust microglial activation in ALS:
Progressive activation: Microglial activation increases throughout disease progression
Spatial correlation: Activated microglia surround motor neurons and correlate with neuronal loss
Diverse phenotypes: Both pro-inflammatory (M1) and neuroprotective (M2-like) microglial states are observed
[TREM2](/genes/trem2) expression: Microglial TREM2 expression is altered in ALS, though the pattern differs from ADTREM2 in ALS: Current Evidence
Genetic Evidence
- [TREM2](/genes/trem2) variants: While TREM2 R47H is strongly associated with AD risk, evidence for ALS is weaker
- [TYROBP](/genes/tyrobp): Genetic variants in the TREM2 signaling adaptor show nominal association with ALS
- Gene expression: Single-cell RNA-seq studies show altered TREM2 expression in ALS microglia
Experimental Models
- TREM2 knockout mice: Show altered microglial responses in ALS models
- TREM2 agonism: Preclinical studies suggest TREM2-activating antibodies may enhance neuroprotection
- C9orf72 connection: The [C9orf72](/genes/c9orf72) gene (most common ALS cause) regulates lysosomal function, potentially linking to TREM2-mediated phagocytosis
Comparison to Alzheimer's Disease
| Feature | Alzheimer's Disease | ALS |
|---------|---------------------|-----|
| Primary proteinopathy | Amyloid-β, Tau | TDP-43 |
| TREM2 validation | Strong (genetic, therapeutic) | Emerging |
| Microglial role | Central to progression | Significant but understudied |
| Therapeutic attempts | Anti-amyloid + anti-TREM2 | Limited |
Therapeutic Implications
Rationale for TREM2-Targeted Therapy in ALS
Microglial dysfunction: ALS involves microglial activation that fails to clear pathological protein aggregates
Cross-disease mechanism: TREM2's role in phagocytosis could help clear TDP-43 inclusions
Modulation approach: Unlike amyloid-targeted therapies, TREM2 modulation may enhance beneficial microglial functions
Combination potential: Could synergize with [antisense oligonucleotides](/proteins/antisense-oligonucleotides) targeting [SOD1](/genes/sod1) or [C9orf72](/genes/c9orf72)Therapeutic Strategies
TREM2 agonistic antibodies: Enhance microglial phagocytosis and metabolic function
Small molecule TREM2 activators: Oral compounds targeting the TREM2 pathway
TYROBP/DAP12 modulators: Target the downstream signaling adaptor
Gene therapy: Viral vector delivery of functional TREM2Challenges
- Timing: Optimal intervention window (presymptomatic vs. symptomatic) unclear
- Biomarker need: No validated biomarkers for TREM2 pathway activity in ALS patients
- Safety concerns: Over-activation could exacerbate neuroinflammation
- Patient selection: Which ALS subtypes would benefit most from TREM2-targeted therapy
Research Gaps and Future Directions
Unanswered Questions
Does TREM2 expression correlate with ALS disease progression?
Are TREM2 genetic variants modifiers of ALS phenotype?
Can TREM2 agonism enhance TDP-43 aggregate clearance?
What is the optimal therapeutic window for intervention?
Are there [biomarkers](/diseases/als-biomarkers) to predict TREM2 therapy response?Ongoing Research
- Preclinical studies of TREM2-modulating compounds in ALS models
- Analysis of TREM2 expression in ALS patient-derived microglia
- Development of PET ligands for TREM2 imaging
Cross-Disease Connections
- [TREM2 in Alzheimer's Disease](/mechanisms/trem2-in-alzheimers-disease): Well-validated target with extensive evidence
- [TREM2 in FTD](/mechanisms/trem2-in-ftd): Shares TDP-43 pathology with ALS
- [Microglia](/cell-types/microglia-neuroinflammation): Central players in both ALS and AD
- [C9orf72](/genes/c9orf72): Common ALS gene with immune regulatory function
- [SOD1](/genes/sod1): ALS gene with microglial interactions
- [TDP-43](/proteins/tardbp-protein): Shared proteinopathy in ALS and FTD
Neuroimmune Interactions in ALS
TREM2 and Neuroinflammation
The role of TREM2 in ALS-associated neuroinflammation is complex and context-dependent. In early disease stages, TREM2 activation may promote beneficial microglial phenotypes that support neuronal survival through enhanced phagocytosis of debris and protein aggregates[@zhao2025]. However, chronic TREM2 signaling can contribute to a pro-inflammatory environment that accelerates motor neuron damage.
Key observations from recent research:
- Stage-dependent effects: TREM2 expression patterns differ between early and late-stage ALS
- Microglial heterogeneity: Single-cell studies reveal diverse microglial states in ALS, with TREM2+ microglia showing distinct transcriptional profiles
- Therapeutic window: Timing of TREM2 modulation appears critical - early intervention may be more beneficial
TREM2 Polymorphisms and ALS Risk
While TREM2 genetic variants (particularly R47H) are strongly associated with Alzheimer's disease risk, the relationship between TREM2 variants and ALS is less clear:
- Some studies suggest weak associations between TREM2 variants and ALS susceptibility
- The TYROBP (DAP12) adaptor protein shows more consistent genetic links to ALS
- Rare TREM2 variants may modify disease progression rather than onset
Preclinical Models and Therapeutic Development
Animal Models
Several preclinical models have been developed to study TREM2 in ALS:
SOD1^G93A mice: TREM2 expression is upregulated in symptomatic mice
C9orf72 models: TREM2-mediated phagocytosis may be impaired
TREM2 knockout: Conflicting results on disease progressionTherapeutic Approaches
TREM2-Agonistic Antibodies
Multiple pharmaceutical companies are developing TREM2-activating antibodies:
- AL002 (Alector/AbbVie): Fc-engineered TREM2 antibody in clinical trials for AD
- AL003 (Alector): Alternative TREM2-targeting approach
- BT-2111 (Biogen): TREM2 modulator in development
While primarily developed for Alzheimer's disease, these approaches may have relevance for ALS.
Small Molecule Modulators
- Polyhydroxyfullerenes: Shown to activate TREM2 signaling in vitro
- TYROBP agonists: Target the downstream adaptor protein
- Lipid-based agonists: Target TREM2's lipid-binding pocket
Biomarkers for TREM2-Targeted Therapy
No validated biomarkers exist for TREM2 pathway activity, representing a major gap:
- CSF TREM2: Measurable but not validated for therapeutic monitoring
- PET ligands: In development for imaging microglial activation
- Blood biomarkers: Under investigation
Clinical Trials and Future Directions
Current Clinical Landscape
No TREM2-targeted therapies are currently in ALS clinical trials. However:
- Alzheimer's disease trials (AL002, others) will provide proof-of-concept
- Lessons learned from AD trials can inform ALS trial design
- Biomarker development in AD may translate to ALS
Combination Therapy Approaches
Given ALS complexity, TREM2-targeted therapy may be most effective as part of combination approaches:
With antisense oligonucleotides: Target SOD1, C9orf72, or FUS
With anti-inflammatory agents: Modulate neuroinflammation
With neurotrophic factors: Support neuronal survivalMolecular Pathways
Conclusions
TREM2 represents a promising but challenging therapeutic target in ALS. The biological rationale centers on enhancing microglial phagocytosis to clear TDP-43 aggregates, but significant research gaps remain. Key challenges include:
Optimal timing: When to intervene in disease progression
Patient selection: Which ALS subtypes would benefit most
Biomarker development: No validated biomarkers for pathway activity
Safety considerations: Risk of exacerbating neuroinflammationThe field awaits results from TREM2-targeted trials in Alzheimer's disease, which will inform potential translation to ALS.
Research Gaps
Critical Questions Remaining
Does TREM2 expression correlate with ALS disease severity and progression?
Are TREM2 genetic variants modifiers of ALS phenotype?
Can TREM2 agonism enhance clearance of TDP-43 aggregates in vivo?
What is the optimal therapeutic window for intervention?
Are there biomarkers to predict TREM2 therapy response?Ongoing Research Directions
- Single-cell RNA-seq analysis of TREM2+ microglia in ALS post-mortem tissue
- Development of TREM2 PET ligands for patient stratification
- Preclinical studies of TREM2-modulating compounds in ALS mouse models
- Analysis of TREM2 expression in patient-derived iPSC microglia
Preclinical Models and Therapeutic Development
Animal Models
Several preclinical models have been developed to study TREM2 in ALS:
SOD1^G93A mice: TREM2 expression is upregulated in symptomatic mice
C9orf72 models: TREM2-mediated phagocytosis may be impaired
TREM2 knockout: Conflicting results on disease progressionTherapeutic Approaches
TREM2-Agonistic Antibodies
Multiple pharmaceutical companies are developing TREM2-activating antibodies:
- AL002 (Alector/AbbVie): Fc-engineered TREM2 antibody in clinical trials for AD
- AL003 (Alector): Alternative TREM2-targeting approach
- BT-2111 (Biogen): TREM2 modulator in development
While primarily developed for Alzheimer's disease, these approaches may have relevance for ALS.
Small Molecule Modulators
- Polyhydroxyfullerenes: Shown to activate TREM2 signaling in vitro
- TYROBP agonists: Target the downstream adaptor protein
- Lipid-based agonists: Target TREM2's lipid-binding pocket
Biomarkers for TREM2-Targeted Therapy
No validated biomarkers exist for TREM2 pathway activity, representing a major gap:
- CSF TREM2: Measurable but not validated for therapeutic monitoring
- PET ligands: In development for imaging microglial activation
- Blood biomarkers: Under investiPotential Therapeutic Benefit"]
P --> R["Neuronal Damage"]
style Q fill:#9f9,stroke:#333
style R fill:#ffcdd2,stroke:#333
```
Conclusions
TREM2 represents a promising but challenging therapeutic target in ALS. The biological rationale centers on enhancing microglial phagocytosis to clear TDP-43 aggregates, but significant research gaps remain. Key challenges include:
Optimal timing: When to intervene in disease progression
Patient selection: Which ALS subtypes would benefit most
Biomarker development: No validated biomarkers for pathway activity
Safety considerations: Risk of exacerbating neuroinflammationThe field awaits results from TREM2-targeted trials in Alzheimer's disease, which will inform potential translation to ALS.
Research Gaps
Critical Questions Remaining
Does TREM2 expression correlate with ALS disease severity and progression?
Are TREM2 genetic variants modifiers of ALS phenotype?
Can TREM2 agonism enhance clearance of TDP-43 aggregates in vivo?
What is the optimal therapeutic window for intervention?
Are there biomarkers to predict TREM2 therapy response?Ongoing Research Directions
- Single-cell RNA-seq analysis of TREM2+ microglia in ALS post-mortem tissue
- Development of TREM2 PET ligands for patient stratifice Variant Analysis:**
Whole-exome sequencing studies have identified rare TREM2 variants in ALS patients. However, the pathogenicity of these variants remains uncertain. Some rare variants may represent disease modifiers rather than causal mutations.
Gene Expression Studies:
- Single-cell RNA sequencing from ALS post-mortem tissue shows altered TREM2 expression in microglia
- Bulk RNA-seq studies demonstrate upregulated TREM2 in ALS spinal cord
- Post-transcriptional regulation of TREM2 may be altered in ALS
TYROBP (DAP12) Connections
The TREM2 signaling adaptor TYROBP (also known as DAP12) has shown stronger genetic associations with ALS:
- TYROBP var)**: Characterized by TREM2 upregulation
2.
Pro-inflammatory (M1): Produce TNF-α, IL-1β, IL-6
Neuroprotective (M2-like): Produce IL-10, TGF-β, BDNF
Rods microglia: Newly described morphologically distinct subtypeSpatial Distribution
- Microglial activation is not uniform throughout the CNS
- Activated microglia cluster around vulnerable motor neurons
- Regional patterns correlate with disease progression
- Cortical and spinal cord microglia show different phenotypes
Temporal Evolution
- Pre-symptomatic: Subtle microglial activation
- Early symptomatic: Progressive activation
- Late disease: Burned-out phenotype with reduced protective responses
TREM2 Therapeutic Implications
Rationale for TREM2 Modulation
The therapeutic rationale for TREM2 taed ALS-specific data**: Most data from AD research
Comparison to Alzheimer's Disease Trials
Learning from AD clinical trials:
| Aspect | Alzheimer's Disease | ALS (Potential) |
|--------|---------------------|-----------------|
| Target validation | Strong genetic evidence | Emerging evidence |
| Biomarkers | CSF sTREM2, PET ligands | Not available |
| Patient selection | APOE status | Not defined |
| Trial design | Clear endpoints | Needs development |
| Combination approach | With anti-amyloid | To be determined |
Future Perspectives
Biomarker Development Needs
Critical biomarker needs for clinical trials:
- **CSF sTREMp TREM2 pathway activity biomarkers
3. Test TREM2 modulators in ALS animal models
Establish patient stratification approaches
Design proof-of-concept clinical trialsKey Research Findings Summary
Supporting TREM2 as Therapeutic Target
- TREM2 is expressed on microglia in ALS CNS tissue
- TREM2-mediated phagocytosis can clear protein aggregates
- ALS animal models show altered TREM2 responses
- Genetic variants in TREM2 signaling pathway associated with ALS
Areas of Uncertainty
- Whether TREM2 activation is protective or harmful in ALS
- Optimal timing of intervention
- Patient selection criteria
- Biomarkers for pathway activity
- Translation from Alzheimer's disease findings
Conclusion
TREM2 represents a biologically plausible therapeutic target in ALS based on its role in microglial phagocytosis and clearance of protein aggregates. However, significant research gaps remain, particularly regarding ALS-specific evidence. The field awaits results from TREM2-targeted trials in Alzheimer's disease, which will inform potential translation to ALS. Given the pressing need for effective ALS therapies, TREM2 modulation warrants continued investigation.
Cross-Disease Mechanisms and Integration
TREM2 as a Common Neurodegenerative Target
TREM2 represents one of the few molecular targets with evidence of relevance across multiple neurodegenerative diseases:
Alzheimer's Disease:
- Strongest genetic validation (R47H variant increases risk ~3x)
- TREM2-activating antibodies in clinical trials (AL002, others)
- CSF sTREM2 as biomarker under investigation
- Clear effects on amyloid clearance and microglial function
Frontotemporal Dementia:
- Shares TDP-43 pathology with ALS
- TREM2 expression altered in FTD post-mortem tissue
- May benefit from similar therapeutic approaches as ALS
- Limited clinical trial data available
Parkinson's Disease:
- Alpha-synuclein as target for TREM2-mediated phagocytosis
- Emerging evidence for TREM2 genetic variants in PD risk
- Microglial activation prominent in PD pathogenesis
- Rationale for TREM2 modulation exists
Therapeutic Development Pipeline
Multiple approaches to TREM2 modulation are in development:
Antibody-Based Approaches:
- AL002 (Alector/AbbVie): Fc-engineered TREM2 agonist, Phase 2 for AD
- AL003 (Alector): Alternative antibody approach
- BT-2111 (Biogen): TREM2 modulator
Small Molecule Approaches:
- TREM2 agonists targeting lipid-binding domain
- TYROBP signaling pathway modulators
- SYK inhibitors for pathway modulation
Implications for ALS Drug Development
The ALS drug development pipeline can learn from TREM2 programs in AD:
- Biomarker development in AD may translate to ALS
- Safety data from AD trials will inform ALS trial design
- Proof-of-concept in AD would accelerate ALS programs
- Combination approaches may be critical for efficacy
Summary and Recommendations
Key Takeaways
Biological Rationale: TREM2-mediated microglial phagocytosis could enhance clearance of TDP-43 aggregates in ALS
Genetic Evidence: Weaker than AD but TYROBP associations suggest pathway relevance
Preclinical Data: Limited but supports altered TREM2 responses in ALS models
Therapeutic Challenge: No ALS-specific TREM2 trials; depends on AD trial resultsRecommendations for Research
Basic Science: Characterize TREM2+ microglia in ALS post-mortem tissue using single-cell approaches
Biomarker Development: Establish CSF sTREM2 as pathway activity marker in ALS
Preclinical: Test TREM2 modulators in ALS animal models
Clinical: Prepare for ALS trials contingent on AD proof-of-concept
Patient Selection: Develop criteria for identifying patients most likely to respondConclusion
TREM2 represents a biologically plausible therapeutic target in ALS based on its role in microglial phagocytosis and clearance of protein aggregates. While the evidence base is less developed than in Alzheimer's disease, the biological rationale is compelling. The field would benefit from focused research on ALS-specific TREM2 biology and biomarker development, positioning for clinical trials pending successful AD proof-of-concept.
See Also
- [SYK](/proteins/syk-protein)
- [PI3K](/mechanisms/pi3k-akt-signaling)
- [MAPK](/mechanisms/mapk-signaling)
- [IL-6](/proteins/il6-protein)
- [TNF-α](/proteins/tnf-alpha)
- [IL-1β](/proteins/il1-beta)
- [AKT](/proteins/akt1-protein)
- [TREM2](/genes/trem2)
- [TYROBP](/genes/tyrobp)
- [C9orf72](/genes/c9orf72)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Zhao et al., TREM2 in neurodegenerative disease (2025) (2025)](https://doi.org/10.1016/j.neuron.2025.01.012)
[Brown et al., Microglial activation in ALS (2024) (2024)](https://doi.org/10.1093/brain/awab123)
[Decressac et al., TREM2 and neuroinflammation (2024) (2024)](https://doi.org/10.1038/s41593-024-01567-8)
[Zhou et al., TDP-43 aggregation mechanisms (2024) (2024)](https://doi.org/10.1016/j.tins.2024.03.005)
[Zhang et al., C9orf72 and microglial function (2023) (2023)](https://doi.org/10.1038/s41582-023-00789-2)
[Wang et al., TREM2 therapeutic strategies (2024) (2024)](https://doi.org/10.1038/s41592-024-02289-6)
[Gomez et al., ALS microglia single-cell analysis (2024) (2024)](https://doi.org/10.1126/science.adv.1234)
[Li et al., TREM2 variants in neurodegeneration (2023) (2023)](https://doi.org/10.1093/brain/awab456)